Needham Maintains Buy on Arcutis Biotherapeutics, Raises Price Target to $40

Benzinga Newsdesk www.benzinga.com Positive 78.9%

Neg 0% Neu 0% Pos 78.9%

Needham analyst Serge Belanger maintains Arcutis Biotherapeutics (NASDAQ:ARQT) with a Buy and raises the price target from $36 to $40.